/stocks — the workspaceLOADING
All CMMB SEC filings, by type → · Earnings date & implied move · Search inside filings
Chemomab Therapeutics Ltd. (CMMB) is a pharmaceutical preparations company. 1 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind CMMB’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Per ADS: one ADS is 80 ordinary shares (20-F filed 2026-03-23), so EPS and book value are multiplied by 80 and the share count divided by it.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from CMMB’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on CMMB plus an auto-SWOT — built from CMMB's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate CMMB using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has CMMB been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as CMMB tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, with EPS multiplied to a per-ADS figure, as its chart title says, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
None of the 5 estimators could run on CMMB's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for CMMB. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for CMMB, so sector medians could not fill the gaps.
Every refusal recorded for CMMB → · How often we decline, and why →
No lawmaker has disclosed a trade in CMMB under the STOCK Act.
Projected from CMMB's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentCMMB files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in CMMB in the latest 13F round.
Of 1 sale in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 1 was filed without it.
| Cohen Neil HarrisDirector | SELL | $7K | view → |
| Mor George AdiChief Executive Officer | BUY | $20K | view → |
2 of the 2 checks that ran found nothing new for CMMB. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Tel Aviv, Israel
Source: the cover page of Chemomab Therapeutics Ltd.’s 20-F filed 2026-03-23, on EDGAR. Filings checked 2026-10-22. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works